S&P Global raises Biocon Biologics’ credit rating to BB+
pre-market1 source ↓written by the desknot a recommendation
Biocon Biologics Limited received an upgrade from S&P Global Ratings, raising its long-term issuer credit rating to BB+ from BB with a stable outlook. This follows a recent equity issuance of approximately US$460 million aimed at settling US$1 billion in compulsorily convertible preference shares. The upgrade reflects a cleaner capital structure and improved credit strength.
Not investment advice. For informational purposes only.